asenapine (Saphris)

From Aaushi
Jump to navigation Jump to search

Indications

Dosage

Adverse effects

Notes

  • cost: $478/month, 10 mg QD (2009)

More general terms

References

  1. Prescriber's Letter 16(10): 2009 Comparison of Atypical Antipsychotics Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=251010&pb=PRL (subscription needed) http://www.prescribersletter.com
  2. 2.0 2.1 FDA MedWatch 09/01/11 Saphris (asenapine maleate): Drug Safety Communication: Serious Allergic Reactions http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm270600.htm
    Prescriber's Letter 18(10): 2011 Saphris (Asenapine) and Serious Allergic Reactions Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=271008&pb=PRL (subscription needed) http://www.prescribersletter.com
  3. 3.0 3.1 3.2 Geriatric Review Syllabus, 8th edition (GRS8) Durso SC and Sullivan GN (eds) American Geriatrics Society, 2013
  4. U.S. FDA Approves SECUADO (asenapine) Transdermal System, the First-and-Only Transdermal Patch for the Treatment of Adults with Schizophrenia. Business Wire. Oct 15, 2019 https://www.businesswire.com/news/home/20191015005668/en/U.S.-FDA-Approves-SECUADO%C2%AE-asenapine-Transdermal-System